Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Robertson Judith J.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Maderis Gail JOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Garcia Peter SOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Farfel Gail MOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Blaschke Terrence FOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Azab MohammadOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
Filings by filing date
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Robertson Judith J.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Maderis Gail JOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Garcia Peter SOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Farfel Gail MOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Blaschke Terrence FOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Azab MohammadOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:5,500Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 10240 Bubb Road CUPERTINO CA 95014 |
Tel: | 1-646-3782928 |
Website: | https://www.durect.com |
IR: | See website |
Key People | ||
James E. Brown President, Chief Executive Officer, Director | Timothy M. Papp Chief Financial Officer, Company Secretary | Judy R. Joice Senior Vice President - Operations and Corporate Quality Assurance | Norman L. Sussman Chief Medical Officer |
Business Overview |
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals. |
Financial Overview |
For the fiscal year ended 31 December 2023, DURECT Corp revenues decreased 56% to $8.5M. Net loss decreased 22% to $27.6M. Revenues reflect Europe segment decrease of 80% to $2.3M, Japan segment decrease of 62% to $559K. Lower net loss reflects Other Research and development decrease of 21% to $28.2M (expense), Selling and general decrease of 11% to $13M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.55 to -$1.05. |
Employees: | 58 as of Mar 26, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $15.41M as of Dec 31, 2023 |
Annual revenue (TTM): | $8.55M as of Dec 31, 2023 |
EBITDA (TTM): | -$36.85M as of Dec 31, 2023 |
Net annual income (TTM): | -$27.62M as of Dec 31, 2023 |
Free cash flow (TTM): | -$34.47M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 31,035,981 as of Mar 26, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |